中慧生物-B 旗下慧尔康欣®作为唯一疫苗入选国家医保创新药品初审名单
AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. This vaccine received new drug application approval in May 2023 and is suitable for individuals aged three and above, aiming to provide protection against H1N1, H3N2, and two types of influenza B viruses. The vaccine has undergone significant upgrades based on traditional vaccines, offering advantages such as high purity and low risk of adverse reactions
According to the announcement from the National Healthcare Security Administration on August 12, 2025, Zhonghui Biological-B (02627) announced that the list of innovative drugs for national commercial health insurance that passed the preliminary review this year includes the only vaccine product—the quadrivalent influenza virus subunit vaccine.
The quadrivalent influenza virus subunit vaccine, marketed under the name HuiErKangXin, received approval for its New Drug Application (NDA) from the National Medical Products Administration of China in May 2023. It is intended for use in individuals aged three and older (with a specification of 15μg/0.5ml in terms of the hemagglutinin concentration of the virus strains) and is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025. It aims to provide broad protection against two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages). This product represents a significant upgrade over traditional virus-inactivated vaccines, offering comprehensive protection, high purity of component antigens, and a low risk of adverse reactions
